OnKure Therapeutics reported zero revenue and a net loss of $17.8 million for the third quarter of 2026. While the EPS loss of $0.36 missed analyst estimates of $0.29, the company significantly strengthened its financial position, ending the quarter with $163.3 million in cash. Management indicated that this capital is sufficient to fund operations into 2029, a substantial extension from previous outlooks.
Key Highlights
- Total cash, cash equivalents, and marketable securities reached $163.3 million, providing a liquidity runway into 2029 compared to the previous late-2026 projection.
- Lead candidates OKI-345 and OKI-355 remain on track for Investigational New Drug (IND) submissions in the first half of 2027.
- Launched the PANORAMA registry, a large-scale observational study to characterize treatment patterns and genetic drivers for patients with vascular anomalies.